Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript

Aine Miller: Julian, thanks for the question on the CYPRESS study. As I alluded to earlier, we’ve already made a lot of great progress activating sites in Europe and the U.S., and we have reengaged a lot of the sites in the U.S. and Europe that we had previously engaged in the prior studies. I would expect that we — the majority of patients will still come from Europe, as it did in the previous program, although we are making efforts to expand our footprint in the U.S. and identify additional qualified sites and I spoke about how we’re going about that in terms of using an AI tool. So, overall, I think, the — more patients will come from Europe, but the actual percentage of the split may differ for a CYPRESS study. Hopefully, that’s helpful.

Julian Harrison: Very helpful. Thank you again.

Operator: Thank you. This does conclude the question-and-answer session of today’s program. I’d like to hand the program back to Mr. Winningham for any further remarks.

Rick Winningham: Yeah. Thank you. I’d like to just thank everyone for joining us today. We’re pleased with the accomplishments of 2023 and look forward to what we can accomplish in 2024, both through effective financial management of the business, as well as the growth of YUPELRI and the execution on the CYPRESS study in order to bring what we believe will be an important medicine to patients with MSA and nOH. Thank you very much.

Operator: Thank you, ladies and gentlemen, for your participation in today’s conference. This does conclude the program. You may now disconnect. Good day.